[ad_1]
A Texas court docket has dismissed a lawsuit accusing pharmaceutical CBD maker GW Prescribed drugs of violating one other firm’s patented technique of cannabidiol extraction for its epilepsy drug Epidiolex.
The 2020 lawsuit from Canadian hashish producer Cover Progress alleged that GW, now a part of Jazz Prescribed drugs, knowingly used a Cover-patented hashish extraction technique.
U.S. District Choose Alan D. Albright dominated in favor of GW on Feb. 25. His ruling leaves a path for Cover to attraction he determination.
Throughout the course of the case, GW produced “confidential technical paperwork” about their manufacturing course of, Albright wrote.
Subsequently, the court docket interpreted the that means of a particular technical time period in Cover’s patent, “CO2 in liquefied type beneath subcritical stress and temperature situations.”
In gentle of GW’s paperwork and the court docket’s interpretation of that time period, the ruling famous, Cover decided it “can not prevail on the problem of infringement.”
Smiths Falls, Ontario-based Cover has the best to attraction the court docket’s interpretation of the patent time period in query.
GW, headquartered in the UK, was acquired by Jazz Prescribed drugs in 2021.
On a Tuesday investor name, Jazz CEO Bruce Cozadd mentioned the corporate was “happy with the place the court docket got here out on the ultimate judgment within the litigation with Cover.”
Epidiolex is comprised of CBD extracted from marijuana grown within the UK.
“They do have the best to attraction that, however we’re definitely happy with the place we stand,” Cozadd added.
A Cover spokesperson mentioned in an announcement to Hemp Trade Every day that, “as this matter remains to be ongoing and earlier than the courts, Cover Progress won’t present additional remark presently.”
Web gross sales of Epidiolex have been price $463.6 million in Jazz’s 2021 fiscal yr, in response to annual monetary outcomes launched Tuesday. Jazz Prescribed drugs trades on the Nasdaq as JAZZ.
Solomon Israel could be reached at solomon.israel@mjbizdaily.com.
[ad_2]